Virios Therapeutics (Virios Therapeutics) Float Percentage Of Total Shares Outstanding : 65.32% (As of Jun. 05, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Virios Therapeutics Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Virios Therapeutics's float shares is 18.13 Mil. Virios Therapeutics's total shares outstanding is 27.76 Mil. Virios Therapeutics's float percentage of total shares outstanding is 65.32%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Virios Therapeutics's Insider Ownership is 4.80%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Virios Therapeutics's Institutional Ownership is 1.59%.

Virios Therapeutics Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Virios Therapeutics's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	18.13	/	27.76
	=	65.32%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Virios Therapeutics (Virios Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Virios Therapeutics Inc (NAS:VIRI) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

44 Milton Avenue, Alpharetta, GA, USA, 30009

Website

https://www.virios.com

Virios Therapeutics Inc is a development-stage biotechnology company. It is focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response such as fibromyalgia. The company is engaged in the development of its product, IMC-1, for people who are suffering from fibromyalgia.

Executives

William Pridgen	director	44 MILTON AVENUE, ALPHARETTA GA 30009
Gregory Scott Duncan	director, officer: Chief Executive Officer	44 MILTON AVENUE, ALPHARETTA GA 30009
Richard James Whitley	director	UAB, CHB 303, 1600 7TH AVENUE SOUTH, BIRMINGHAM AL 35233-1711
Angela Walsh	officer: VP of Finance	44 MILTON AVENUE, ALPHARETTA GA 30009
De La Rosa Abel	director	44 MILTON AVENUE, ALPHARETTA GA 30009
John C Thomas	director	8601 SIX FORKS ROAD, SUITE 160, RALEIGH NC 27615
David R Keefer	director	44 MILTON AVENUE, ALPHARETTA GA 30009
Ralph Grosswald	officer: Vice President of Operations	44 MILTON AVENUE, ALPHARETTA GA 30009
Roger Michael Gendreau	officer: Chief Medical Officer	44 MILTON AVENUE, ALPHARETTA GA 30009
Richard Alan Burch	director	44 MILTON AVENUE, ALPHARETTA GA 30009